MediPharm Labs Corp.
LABS.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 6.45M | 7.93M | 8.31M | 8.53M | 7.53M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.45M | 7.93M | 8.31M | 8.53M | 7.53M |
| Cost of Revenue | 4.07M | 5.21M | 6.46M | 6.10M | 4.30M |
| Gross Profit | 2.38M | 2.73M | 1.85M | 2.44M | 3.23M |
| SG&A Expenses | 3.08M | 3.13M | 3.27M | 5.18M | 3.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -1.40K | 256.80K | 137.20K | -56.40K | -115.70K |
| Total Operating Expenses | 7.16M | 8.63M | 9.90M | 11.25M | 7.84M |
| Operating Income | -714.80K | -693.60K | -1.59M | -2.72M | -305.90K |
| Income Before Tax | -623.50K | -1.41M | -1.56M | -2.72M | -269.70K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -623.50K | -1.41M | -1.56M | -2.72M | -269.70K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -623.50K | -1.41M | -1.56M | -2.72M | -269.70K |
| EBIT | -714.80K | -693.60K | -1.59M | -2.72M | -305.90K |
| EBITDA | -446.60K | -416.00K | -1.29M | -2.42M | -9.80K |
| EPS Basic | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 424.86M | 421.70M | 420.76M | 415.35M | 415.12M |
| Average Diluted Shares Outstanding | 424.86M | 421.70M | 420.76M | 415.35M | 415.12M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |